Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
ACPH - oktober mogelijke goedkeuring FDA voor Barhemsys
Volgen
Op 5 oktober zou de FDA zich uitspreken over de goedkeuring van de FDA voor Barhemsys. Een middel dat zou gebruikt worden om te misselijkheid bij operaties te verhelpen, simpel en kort uitgelegd. Een gigantische markt, weinig concurrentie en uitstekende fase 3 resultaten. Degroof Petercam geeft o.a. een koersdoel van 4.8 €. Edison investment research geeft zelfs een koersdoel van 10,9 €. De werkzame stof (hoofdbestanddeel) Barhemsys is reeds goedgekeurd onder een ander medicijn dat gebruikt wordt voor mensen met schizofrenie. De CEO zei bij de IPO in maart dit jaar dat hij de goedkeuring als een cadeau voor de aandeelhouders beschouwde, want hij is er gerust in. IPO was rond de 3.6 €, waar we nu terug rond schommelen. Zij hebben momenteel (slechts) 1 ander product in de pipeline, dat qua marktpotentieel nog veelbelovender zou zijn. Gezien de korte tijd t.e.m. eventuele goedkeuring heb ik enkele weken geleden op 3,... een eerste positie ingenomen. Lijkt me een zeer veelbelovend aandeel. Benieuwd naar andere meningen hier.
TER INFO moesten er lezers zijn die mee volgen:www.edisoninvestmentresearch.com/?ACT... Koersdoel Edison 10.9 €. Denk dat er veel zijn die deze onbekende parel onterecht links laten liggen. Aftellen naar 5 oktober en wat meer animo hier.
Waar vind ik de trial resultaten?
14 September 2018 Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia Cambridge, UK and Indianapolis, US – 14 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial with BARHEMSYS™ (intravenous amisulpride) have been published in the online edition of the leading peer-reviewed journal Anesthesia & Analgesia (Candiotti et al1). Positive headline results were first announced by the Company in August 2016. The pivotal Phase 3 trial met its primary endpoint, demonstrating that BARHEMSYS, at two doses tested (5 mg and 10 mg), was significantly superior to placebo at treating established post-operative nausea & vomiting (PONV) in patients at low-to-moderate risk of PONV who had not received any prior prophylaxis. BARHEMSYS at both doses also showed a safety profile similar to placebo. A New Drug Application (NDA) for BARHEMSYS, including data from this and three other positive Phase 3 trials, is currently under review by the US Food and Drug Administration (FDA), with a target date of 5 October 2018 to complete its review. The extensive clinical trial programme has investigated the safety and efficacy of BARHEMSYS in the treatment of established PONV, whether or not prior prophylaxis was given, and the prevention of PONV, alone or in combination with other antiemetics. “PONV is a common complication of surgery affecting millions of patients who undergo general anaesthesia and represents an important challenge for physicians and patients. I am very encouraged by the results seen in this and other trials with BARHEMSYS, which could provide a valuable additional option for treating PONV,” said Professor Keith Candiotti MD, Professor of Anesthesiology and Interim Chair of the Anesthesiology faculty at the University of Miami’s Miller School of Medicine and chief investigator of the study. Dr Gabriel Fox, Acacia Pharma’s Chief Medical Officer, added: “This is the fourth publication to come out of our rigorous, 3,300-patient BARHEMSYS clinical programme, which demonstrated efficacy in both the prophylaxis and treatment of PONV. BARHEMSYS is the first new agent in more than 20 years to be studied in prospective, randomised trials of the treatment of active PONV and we are therefore especially excited by the possibility of giving healthcare providers and patients another choice in that setting.” Note: The tradename BARHEMSYS™ has received conditional approval by the US FDA and has replaced the previously used BAREMSIS®. Summary of the trial and results The Phase 3 study (ClinicalTrials.gov identifier: NCT02449291) was a double-blind, randomised, placebo-controlled trial conducted at 21 sites in Europe and North America. It included 1,988 adult patients undergoing elective surgery under general anaesthesia who had a low-to-moderate risk of PONV based on the Apfel risk factor scoring system2. Patients who then suffered PONV were randomised equally to one of three single-dose, IV regimens: placebo or 5 mg or 10 mg amisulpride. A total of 560 patients were randomised to receive one of the study medications and were eligible for intent-to-treat analysis. The primary endpoint was complete response (CR), defined as no emesis in the period 30 minutes to 24 hours after study drug treatment and no use of rescue medication in the entire 24-hour period. The trial met its primary endpoint: CR occurred in 39/181 patients (21.5%) in the placebo group compared to 60/191 patients (31.4%; p=0.016) and 59/188 patients (31.4%; p=0.016) in the amisulpride 5 mg and 10 mg groups, respectively. One or more treatment-emergent adverse events were experienced by 39.8% of patients in the 5 mg group and 42.0% of the 10 mg group, compared to 53.0% of the placebo group. The only adverse events to occur in 5% or more of the patients in any group were flatulence, nausea occurring more than 24 hours after treatment, constipation and infusion site pain, all of which were similar between the groups. References Candiotti KA, Kranke P, Bergese SD, et al. Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Amisulpride as Treatment of Established Postoperative Nausea and Vomiting in Patients Who Have Had No Prior Prophylaxis. Anesth Analg 2018; doi: 10.1213/ANE.0000000000003733 [epub ahead of print]Apfel, C.C., Läärä, E., Koivuranta, M., Greim, C.A., Roewer, N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999, 91(3):693-700. About BARHEMSYS BARHEMSYS comprises a low dose intravenous formulation of the marketed dopamine antagonist amisulpride, which Acacia Pharma has developed for the completely new, patent-protected uses of prevention and treatment of PONV. A New Drug Application (NDA) submission for BARHEMSYS, including data from four positive Phase 3 studies and more than 3,300 surgical patients and healthy volunteers, is currently under review by the US Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of 5 October 2018 to complete its review. The Company is seeking approval of BARHEMSYS for: Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or who have not received prophylaxis; andPrevention of PONV, either alone or in combination with an antiemetic of a different class.
Bovenstaand artikel werd gepubliceerd, wat ook voor een spike zorgde, ik heb het grootste deel even geplaatst (rest waren nog algemene bepalingen).
www.drugs.com/clinical_trials/acacia-... even de historiek fase 2 data meegeven ...
www.drugs.com/nda/baremsis_180104.html Acacia Pharma Announces FDA Acceptance of NDA Filing For Baremsis for the Management of Post-Operative Nausea & Vomiting
www.manufacturingchemist.com/news/art... Acacia Pharma secures $30 million funding 2-Jul-2018
Elvisfan schreef op 28 september 2018 11:05 :
www.youtube.com/watch?v=INCoxWEGTNk En Elvisfan, wat denk je, goede tip tot nu toe? :-) Je hebt al 5% winst ongeveer hoop ik? Laat ons hopen dat het vuurwerk volgende week écht begint. Vraagje aan de andere volgers: waarom wordt het koersdoel van 10,9€ niet opgenomen door diverse beurssites (trivano, beursduivel, iex)?
Gisteren was de beurs al toe, nu is een.een beetje de vraag instappen bij +5%??? Tegen sluiting nog eens kijken dan vlakt alles wat meer uit..
Fintech 13 schreef op 28 september 2018 12:16 :
[...]
En Elvisfan, wat denk je, goede tip tot nu toe? :-)
Je hebt al 5% winst ongeveer hoop ik?
Laat ons hopen dat het vuurwerk volgende week écht begint.
Vraagje aan de andere volgers: waarom wordt het koersdoel van 10,9€ niet opgenomen door diverse beurssites (trivano, beursduivel, iex)?
ik heb al winst jazeker, bedankt; ik heb vandaag en gisteren heel wat gelezen; die FDA approval komt haast zeker, ik verwacht volgende week naar vrijdag toe zeker nog een stijging en hoop dat het vrijdag ontploft en kermis is!
Amai die gaan nu echt wel spijtig dat we gisteren niet zijn kunnen instappen.
Mopperaar schreef op 28 september 2018 12:27 :
Gisteren was de beurs al toe, nu is een.een beetje de vraag instappen bij +5%???
Tegen sluiting nog eens kijken dan vlakt alles wat meer uit..
idd, je kan nu beter wachten tot de late namiddag; hoogste koers was 3.90, neem van mij aan dat we die koers zeker zullen zien volgende week !!!
Mopperaar schreef op 28 september 2018 13:21 :
Amai die gaan nu echt wel spijtig dat we gisteren niet zijn kunnen instappen.
en mopperaar, vergeet ook jij niet een beetje reclame te maken op het Argenx, GLPG en Mithra forum, hahaha
Profile CEO Dr Julian Gilbert, heeft al heel wat waters doorzwommen ... Julian is Chief Executive Officer & Co-Founder of Acacia Pharma. He has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience, Mundipharma, British Technology Group (BTG) and Smith Kline & French (now GlaxoSmithKline). Prior to co-founding Acacia Pharma, he was co-founder and commercial director of Arakis which was sold to Sosei in 2005 for £107 million. Arakis successfully developed a pipeline of clinical opportunities and out-licensed its lead project to Novartis (repurposed glycopyrronium for chronic obstructive pulmonary disease (COPD) - now branded Seebri® and Ultibro® Breezhalers®). Julian is one of the inventors on the new use glycopyrronium patent and led the commercialisation to Novartis. He also led the commercialisation of AD923 (sub-lingual fentanyl spray) for cancer breakthrough pain to Mundipharma. He has a degree in pharmacy and a PhD in pharmaceutics both from the University of Nottingham.
Mopperaar schreef op 28 september 2018 13:21 :
Amai die gaan nu echt wel spijtig dat we gisteren niet zijn kunnen instappen.
het kan nog altijd he
Elvisfan schreef op 28 september 2018 13:40 :
[...]
het kan nog altijd he
toen ik Mithra gekocht had aan 23 (toen ze reeds meer dan verdubbeld waren de maanden voordien), dacht ik ook vrij laat te zijn, de rest van het verhaal ken je :-))
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
-0,10%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers